Revvity

#Human cell models #Mergers and acquisitions #Preclinical development #Revvity

Revvity acquires human cell model specialist

Revvity has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specialising in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases.   The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio,… Read More

#Business & Investment #News

Antibody drug conjugates
#Antibody drug conjugate (ADC) #Biologics #Revvity

Preclinical screening platforms for Antibody-Drug Conjugate therapeutics

This advertorial is sponsored by Revvity. Antibody Drug Conjugates (ADCs) represent one of the most rapidly expanding oncology therapeutic categories. Hundreds of candidates are undergoing active clinical development, with about two hundred companies engaged in ADC development1. Recent regulatory adjustments within the pharmaceutical industry in the US have begun to… Read More

#Exclusive Content

Human eye
#Clinical trial #Ophthalmology #Preclinical development #Revvity

Preclinical advancements in ophthalmology drug development

Dr Jess Pesner and Caleb Proctor, Revvity, explore the use of in vivo, in vitro models, and in silico models in the quest for new treatments for diseases of the eye. Within drug and device approval paths, regulated steps protect the well-being of the public and offer hope for those who may be battling a disease or a life event that may currently not… Read More

#Exclusive Content

#Assays #Drug discovery #Oncology #Revvity #SLAS2026 #SPT Labtech

SLAS2026: Day One Round-Up  

DDW covers some of the biggest announcements from the first day of SLAS2026.     Carterra launches high-throughput SPR instrument   High-throughput technology provider Carterra  launched its Carterra Vega High-Throughput Surface Plasmon Resonance (HT-SPR) instrument – the industry’s first 48-channel SPR platform. The instrument has been designed to deliver 12-fold higher throughput versus the… Read More

#News

#Drug discovery #High throughput screening #Revvity #SLAS2026

Revvity launches high-impact discovery platform 

Revvity launched multiple new discovery platforms and technologies at SLAS2026, all designed to accelerate high-throughput drug discovery workflows.   The company debuted its Opera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation.   The Opera Phenix OptIQ high-content screening system is designed to reduce bottlenecks in phenotypic screening and… Read More

#News

Scientist working with multi well plate for cell culture in the lab
#Antibody drug conjugate (ADC) #Drug discovery #GPCRs #Reagents #Revvity

Revvity launches new reagents for GPCR research

Revvity has launched pHSense reagents, designed to advance internalisation studies in drug discovery.   pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs).  Developed for use with standard plate readers, pHSense reagents combine a… Read More

#News

#Collaboration #Genomics #Genomics England #NHS #Public health #Research #Revvity

Collaboration to advance UK genomics research 

Revvity has announced an expansion of its working relationship with Genomics England that leverages both organisations' expertise and resources to advance critical genomic initiatives across the United Kingdom.   Building on the parties’ long and productive work history, this collaboration is dedicated to accelerating Genomics England’s research programmes, supporting diverse areas… Read More

#Business & Investment #News

#Imaging #Revvity

Imaging technologies to drive discoveries 

Revvity has launched an imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three imaging systems.   These systems include the next-generation IVIS Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, as well as the QuantumTM GX3 microCT. Globally,… Read More

#News

#Healthcare #Life sciences #NHS #Revvity #UK

Revvity opens Scientific Centre of Excellence for genomics

Global health science solutions company Revvity, PerkinElmer’s Life Science and Diagnostics business’ new name and branding, has announced the establishment of a Scientific Centre of Excellence in Cambridge, UK.   Focused on driving genomic insights to accelerate therapeutic discovery, Revvity’s Scientific Centre of… Read More

#News

Cutting the red ribbon
#Drug discovery #Omics #PerkinElmer #Preclinical development #Revvity

PerkinElmer’s Life Science and Diagnostics business becomes Revvity

PerkinElmer’s Life Science and Diagnostics business has revealed its new name and branding. Revvity has now officially launched as a science-based solutions company. Based on two words, ‘revolutionise’ (rev) and ‘vita’ (vit) meaning ‘life’ in Latin, Revvity will provide reagents, consumables, assays, instruments and software to customers from pharma and biotech,… Read More

#Business & Investment #News